BAUSCH+ Health

Bausch Health Announces Second Quarter 2026 Results, Raises Guidance

July 29, 2026

- **Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)[1] basis over the prior year period**
- **GAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 million**
- **GAAP Earnings per Diluted Share Attributable to Bausch Health of $0.68 compared to $0.40 in the prior year period; Adjusted Earnings per Diluted Share (non-GAAP)[1] of $1.26 compared to $0.90 in the prior year period, an increase of 40%**
- **Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)[1] of $1,075 million, up 28% on a Reported basis over the prior year period**

BAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2026 RESULTS

- **Delivered thirteenth consecutive quarter of year-over-year Revenue growth, with Revenue up 16% on a Reported basis and 13% on an Organic (non-GAAP)[1] basis**
- **Net Income increased $84 million over the prior year period, and Adjusted EBITDA (non-GAAP)[1] grew 28%**
- **Generated $517 million in Cash Provided by Operating Activities and $471 million in Adjusted Cash Flows from Operations (non-GAAP)[1]**
- **Raising full-year 2026 Revenue, Adjusted EBITDA (non-GAAP)[1], and Adjusted Cash Flows from Operations (non-GAAP)[1] guidance**

LAVAL, QC, July 29, 2026 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2026 financial results and other key updates from the quarter.

"The second quarter marks our thirteenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, reflecting the strength of our portfolio, disciplined execution, and the dedication of our teams around the world. We delivered our highest Revenue and Adjusted EBITDA growth rates in the past three years, generated our strongest Adjusted Cash Flow from Operations since Q4 2024, and reduced Net Debt by one of our largest amounts since our 2022 debt refinancing. This performance strengthens our financial flexibility and supports continued investment in our business, our pipeline, and business development opportunities. We remain focused on driving long-term value creation," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

Second Quarter 2026 Revenue Performance

Total consolidated reported revenues were $2.85 billion for the second quarter of 2026, compared with $2.53 billion in the second quarter of 2025, an increase of $322 million, or 13%. Excluding the impact of foreign exchange of $25 million, acquisitions of $35 million, and divestitures and discontinuations of $7 million, revenue increased 11% on an organic[1] basis compared with the second quarter of 2025.

[1] This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news

release for a reconciliation of this and other non-GAAP measures and ratios to the most directly comparable GAAP measure.

Read More

View original release here:
https://www.prnewswire.com/news-releases/bausch-health-announces-second-quarter-2026-results-raises-guidance-302838191.html

Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com
908-569-3692

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED